Home Cart Sign in  
Chemical Structure| 2055597-12-9 Chemical Structure| 2055597-12-9

Structure of ASN007
CAS No.: 2055597-12-9

Chemical Structure| 2055597-12-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ASN007 (ERK-IN-3) is an effective orally active ERK inhibitor specifically targeting ERK1/2. It inhibits ERK1/2 activity with a low IC50 value, showing potential for studying RAS mutation-driven cancers. ASN007 aids in exploring the role of the ERK signaling pathway in cancer and therapeutic strategies.

Synonyms: ERK-IN-3

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ASN007

CAS No. :2055597-12-9
Formula : C22H25ClFN7O2
M.W : 473.93
SMILES Code : O=C(C1=CN(C2=NC(NC3CCOCC3)=NC=C2C)C=N1)N[C@@H](C4=CC(F)=CC(Cl)=C4)CN
Synonyms :
ERK-IN-3
MDL No. :MFCD32878259

Safety of ASN007

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of ASN007

MAPK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
JeKo-1 1.4 μM 72 h To evaluate the antiproliferative activity of ASN007 in lymphoma cell lines, results showed that ASN007 had significant antiproliferative effects on JeKo-1 cell line Cell Rep Med. 2021 Jul 21;2(7):100350.
H1975/OR cells 500 nM 24 h ASN007 treatment induced cell cycle arrest at G0/G1 phase and apoptosis Invest New Drugs. 2022 Apr;40(2):265-273

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HCT116 xenograft model Oral 25 mg/kg Twice daily for 35 days To evaluate the antitumor efficacy of ASN007 in KRAS-mutant tumor models, results showed that ASN007 significantly inhibited tumor growth Cell Rep Med. 2021 Jul 21;2(7):100350.
BALB/c female nude mice PC9/ER xenograft model Oral 50 mg/kg 5 days per week for 28 days ASN007 alone or in combination with erlotinib significantly inhibited tumor growth, with combination therapy completely inhibiting tumor growth Invest New Drugs. 2022 Apr;40(2):265-273

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.55mL

2.11mL

1.06mL

21.10mL

4.22mL

2.11mL

 

Historical Records

Categories